SAN FRANCISCO, April 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that positive preclinical and clinical results for its pipeline programs will be presented at numerous medical and scientific meetings over the coming months. These presentations will highlight Nektar's novel therapeutic candidates in the areas of oncology, anti-infectives and central nervous system (CNS), which leverage Nektar's innovative small molecule PEGylation and liquid aerosol platforms.
The data presentations are as follows:
-- April 12-16, 2008: Presentation of Positive Preclinical Data for
NKTR-102 (PEG-irinotecan) at the American Association for Cancer Research
(AACR) Annual Meeting in San Diego, California:
Poster #766: "Enhanced anti-tumor activity of NKTR-102, a novel
PEGylated-irinotecan, when administered in combination with
bevacizumab in a mouse model of human colorectal tumors"
Poster #5741: "NKTR-102, a novel PEGylated-irinotecan, has an
enhanced pharmacokinetic profile with reduced gastrointestinal and
hematopoietic toxicity compared to irinotecan with repeat dosing"
Poster #5742: "NKTR-102, a novel PEGylated-irinotecan, has a
superior acute safety, tolerability, and pharmacokinetic profile
compared to irinotecan"
-- May 8-10, 2008: Presentation of Phase 1 Clinical Trial Multi-Dose
Safety Data for NKTR-118 (oral PEG-naloxol) in Opioid Bowel Dysfunction at
the American Pain Society (APS) Meeting in Tampa, Florida:
Poster #210: "Results from a phase I, double-blind, randomized,
placebo-controlled, multiple-dose study evaluating the safety,
tolerability, and pharmacokinetics of oral doses of NKTR-118"
-- May 16-21, 2008: Positive Results from Phase 2 Clinical Trials for
NKTR-061 (inhaled amikacin) to be presented at the American Thoracic
Society (ATS) Meeting in Toronto, Canada:
Poster #516: "NKTR-061 (inhaled amikacin) BID achieves high
epithelial lining fluid concentrations in pneumonic portions of
Poster #517: "Evidence of High Amikacin Lung Deposition in
Mechanically Ventilated Patients (MVP) with Pneumonia and Healthy
Subjects (HS) dosed using NKTR-061"
Poster #518: "High in vivo amikacin lung deposition after NKTR-061
dosing correlates with in vitro aerosol characterization"
-- Positive Phase 1 Clinical data for NKTR-102 (PEG-irinotecan) will also be published at additional oncology conferences this year.
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
This press release contains forward-looking statements regarding
upcoming presentations of preclinical and clinical results at medical and
scientific meetings and the potential of Nektar's development technology
platforms and product pipeline. These forward-looking statements involve
risks and uncertainties, including but not limited to: (i) Nektar's
proprietary product candidates and those of certain of its partners are in
the early phases of clinical development and pre-clinical development and
the risk of failure is high and can unexpectedly occur at any stage, (ii)
the timing or success of commencing or concluding clinical trials is
subject to a number of uncertainties including but not limited to clinical
design, patient enrollment, regulatory requirements and clinical outcomes,
(iii) Nektar's or its partners' clinical trials may fail to meet minimum
clinical end points, (iv) Nektar or its partners may ultimately fail to
obtain regulatory approval of one or more product candidates, (v) Nektar's
patent applications for its proprietary or partner product candidates may
not issue, patents that have issued may not be enforceable or sufficiently
broad as to protect against competitive products, or intellectual property
licenses from third parties may be required in the future, (vi) the outcome
of any existing or future intellectual property or other litigation related
to Nektar's proprietary product candidates, and (vii) potential competition
from existing approved products (branded or generic) or product candidates
under development by other companies could negatively impact the commercial
potential of Nektar's product candidates due to such competitive factors as
efficacy and safety profiles, pricing, and reimbursement by third party
payers. These forward-looking statements involve substantial risks and
uncertainties, including those risks and uncertainties that are detailed in
Nektar's reports and other filings with the SEC including its most recent
Annual Report on Form 10-K. Actual results could differ materially from the
forward-looking statements contained in this press release. Nektar
undertakes no obligation to update forward-looking statements, whether as a
result of new information, future events, or otherwise. No information
regarding or presented at the medical and scientific meetings referred to
above (or contained at the Internet links provided) is intended to be
incorporated by reference in this press release.
Tim Warner (650) 283-4915 or email@example.com
Stephan Herrera (415) 488-7699 or firstname.lastname@example.org
Jennifer Ruddock (650) 631-4954 or email@example.com
|SOURCE Nektar Therapeutics|
Copyright©2008 PR Newswire.
All rights reserved